Author response for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"
2020 ◽
2020 ◽
2019 ◽
2020 ◽
2019 ◽
2019 ◽
2020 ◽
2020 ◽
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial
2020 ◽
